OTCPK:DTXM.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.

Share Price & News

How has Deltex Medical Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DTXM.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

DTXM.F

0.2%

US Medical Equipment

0.4%

US Market


1 Year Return

n/a

DTXM.F

24.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: Insufficient data to determine how DTXM.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how DTXM.F performed against the US Market.


Shareholder returns

DTXM.FIndustryMarket
7 Day0%0.2%0.4%
30 Day-71.4%7.4%6.1%
90 Day-66.7%7.6%8.9%
1 Yearn/a25.9%24.8%20.5%17.8%
3 Yearn/a75.8%71.2%42.3%32.9%
5 Yearn/a143.9%124.8%84.2%63.4%

Price Volatility Vs. Market

How volatile is Deltex Medical Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Deltex Medical Group undervalued compared to its fair value and its price relative to the market?

2.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: DTXM.F ($0.01) is trading above our estimate of fair value ($0.01)

Significantly Below Fair Value: DTXM.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DTXM.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: DTXM.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DTXM.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DTXM.F is good value based on its PB Ratio (2.7x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Deltex Medical Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.8%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if DTXM.F's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if DTXM.F's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DTXM.F's revenue (13.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: DTXM.F's revenue (13.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DTXM.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Deltex Medical Group performed over the past 5 years?

38.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DTXM.F is currently unprofitable.

Growing Profit Margin: DTXM.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DTXM.F is unprofitable, but has reduced losses over the past 5 years at a rate of 38.4% per year.

Accelerating Growth: Unable to compare DTXM.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DTXM.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: DTXM.F has a negative Return on Equity (-21.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Deltex Medical Group's financial position?


Financial Position Analysis

Short Term Liabilities: DTXM.F's short term assets (£2.7M) exceed its short term liabilities (£2.3M).

Long Term Liabilities: DTXM.F's short term assets (£2.7M) exceed its long term liabilities (£1.5M).


Debt to Equity History and Analysis

Debt Level: DTXM.F's debt to equity ratio (54.8%) is considered high.

Reducing Debt: DTXM.F's debt to equity ratio has increased from 54.1% to 54.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DTXM.F has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DTXM.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Deltex Medical Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DTXM.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DTXM.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DTXM.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DTXM.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DTXM.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Andy Mears (51 yo)

2.33yrs

Tenure

UK£183,123

Compensation

Mr. Andrew Jonathan Mears, also known as Andy, has been Chief Executive Officer and Director of Deltex Medical Group plc since June 13, 2018. Mr. Mears was Managing Director of Deltex Medical Group plc sin ...


CEO Compensation Analysis

Compensation vs Market: Andy's total compensation ($USD238.92K) is below average for companies of similar size in the US market ($USD578.04K).

Compensation vs Earnings: Andy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Andrew Mears
CEO & Director2.33yrsUK£183.12k0.53%
£ 42.6k
David Philip Moorhouse
Finance Director0.92yrUK£125.19k0.16%
£ 12.7k
Marion Lee
Human Resources Director5.5yrsno datano data

2.3yrs

Average Tenure

Experienced Management: DTXM.F's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Andrew Mears
CEO & Director2.33yrsUK£183.12k0.53%
£ 42.6k
David Philip Moorhouse
Finance Director0.92yrUK£125.19k0.16%
£ 12.7k
Nigel Keen
Independent Chairman24.75yrsUK£33.33k12.33%
£ 992.5k
Duncan Nichol
Independent Non Executive Director16.25yrsUK£24.00k0.52%
£ 42.2k
Christopher Jones
Independent Non-Executive Director5.33yrsUK£24.00k0.10%
£ 8.1k
Mark Wippell
Independent Non-Executive Director6.33yrsUK£24.00k0.47%
£ 38.0k
Charles Cazalet
Independent Non Executive Director12.5yrsUK£24.00k1.79%
£ 144.1k

6.3yrs

Average Tenure

69.5yo

Average Age

Experienced Board: DTXM.F's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DTXM.F insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Deltex Medical Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Deltex Medical Group plc
  • Ticker: DTXM.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£6.167m
  • Listing Market Cap: UK£8.046m
  • Shares outstanding: 524.87m
  • Website: https://www.deltexmedical.com

Number of Employees


Location

  • Deltex Medical Group plc
  • Terminus Road
  • Chichester
  • West Sussex
  • PO19 8TX
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DTXM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2000
DEMGAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJul 2000

Biography

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United State ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 00:18
End of Day Share Price2020/10/16 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.